There are presently no approved agents that directly target the oncogenic MUC1-C protein. Genus Oncology has focused on developing agents against MUC1-C based on the weight of evidence that human cancer cancer cells are dependent on this oncoprotein for their growth, survival and self-renewal. Genus Oncology has taken two broad approaches to target MUC1-C: (i) development of agents that inhibit function of the cytoplasmic domain, and (ii) generation of monoclonal antibodies (MAbs) against the non-shed extracellular domain.
The MUC1-C cytoplasmic domain contains a CQC motif that is necessary and sufficient for MUC1-C (i) homodimerization, (ii) nuclear localization and (iii) function as an oncoprotein. Based on these findings, we developed cell-penetrating peptides...more
The generation of MAbs against the MUC1-C extracellular domain (MUC1-C/ED) provides an opportunity for developing novel therapeutic approaches that target MUC1-C on the surface of cancer cells. In this way...more
Genus Oncology has developed a panel of monoclonal antibodies against the MUC1-C cytoplasmic domain to identify patients with tumors that overexpress MUC1-C and are candidates for our therapeutic approaches. more...
For well over a decade, Genus Oncology has aggressively pursued intellectual property protection relating to various aspects of MUC1’s biologic activity. In conjunction with our academic partner – The Dana-Farber Cancer Institute – we have filed numerous patents...more